ACAD
32.04
-0.55
-1.69%
AEMD
0.237
+0.01
+4.405%
APRI
1.83
-0.04
-2.14%
ARNA
4.31
-0.06
-1.37%
ATEC
1.42
-0.03
-2.07%
CNAT
6.81
-0.31
-4.35%
CRXM
0.194
-0.001
-0.3079%
CYTX
1.17
-0.01
-0.85%
DXCM
61.49
-0.85
-1.36%
GNMK
12.27
-0.71
-5.47%
HALO
14.67
+0.39
+2.73%
ILMN
182.21
-3.43
-1.85%
INNV
0.142
+0.002
+1.0714%
INO
8.47
+0.31
+3.80%
ISCO
0.054
-0.004
-6.574%
ISIS
63.18
-0.49
-0.77%
LGND
77.45
+0.34
+0.44%
LPTN
2.34
-0.13
-5.26%
MBVX
1.91
+0.04
+2.1444%
MEIP
1.79
0.00
0.00%
MNOV
3.55
+0.05
+1.43%
MRTX
29.11
-0.21
-0.72%
MSTX
0.461
-0.025
-5.0515%
NBIX
39.9
+0.19
+0.48%
NUVA
45.6
-0.39
-0.85%
ONCS
0.326
-0.01
-2.8358%
ONVO
3.59
+0.05
+1.41%
OREX
7.68
-0.15
-1.92%
OTIC
34.6
-0.76
-2.15%
QDEL
26.15
-0.83
-3.08%
RCPT
173.44
+8.55
+5.19%
RGLS
17.45
+0.51
+3.01%
RMD
71.39
-0.39
-0.54%
SCIE
0.03
0.00
0.00%
SPHS
0.59
+0.01
+1.92%
SRNE
11.39
-0.17
-1.47%
TROV
6.75
-0.06
-0.88%
VICL
0.94
0.00
-0.52%
VOLC
17.99
0.00
0.00%
ZGNX
1.44
+0.07
+5.11%
ACAD
32.04
-0.55
-1.69%
AEMD
0.237
+0.01
+4.405%
APRI
1.83
-0.04
-2.14%
ARNA
4.31
-0.06
-1.37%
ATEC
1.42
-0.03
-2.07%
CNAT
6.81
-0.31
-4.35%
CRXM
0.194
-0.001
-0.3079%
CYTX
1.17
-0.01
-0.85%
DXCM
61.49
-0.85
-1.36%
GNMK
12.27
-0.71
-5.47%
HALO
14.67
+0.39
+2.73%
ILMN
182.21
-3.43
-1.85%
INNV
0.142
+0.002
+1.0714%
INO
8.47
+0.31
+3.80%
ISCO
0.054
-0.004
-6.574%
ISIS
63.18
-0.49
-0.77%
LGND
77.45
+0.34
+0.44%
LPTN
2.34
-0.13
-5.26%
MBVX
1.91
+0.04
+2.1444%
MEIP
1.79
0.00
0.00%
MNOV
3.55
+0.05
+1.43%
MRTX
29.11
-0.21
-0.72%
MSTX
0.461
-0.025
-5.0515%
NBIX
39.9
+0.19
+0.48%
NUVA
45.6
-0.39
-0.85%
ONCS
0.326
-0.01
-2.8358%
ONVO
3.59
+0.05
+1.41%
OREX
7.68
-0.15
-1.92%
OTIC
34.6
-0.76
-2.15%
QDEL
26.15
-0.83
-3.08%
RCPT
173.44
+8.55
+5.19%
RGLS
17.45
+0.51
+3.01%
RMD
71.39
-0.39
-0.54%
SCIE
0.03
0.00
0.00%
SPHS
0.59
+0.01
+1.92%
SRNE
11.39
-0.17
-1.47%
TROV
6.75
-0.06
-0.88%
VICL
0.94
0.00
-0.52%
VOLC
17.99
0.00
0.00%
ZGNX
1.44
+0.07
+5.11%
Home » Hugo Villar, Ph.D., MBA-Bio

Hugo Villar, Ph.D., MBA-Bio

Hugo O. Villar Ph.D., MBA is director for Science and Technology programs at UC San Diego Extension. He is also President of Altoris, Inc. a San Diego based specializing in information management for the biotech and pharmaceutical industries and providing consulting on discovery technologies. He was Vice President for Chemoproteomics at Triad Therapeutics and Vice President of Discovery Technologies at Telik, Inc. His work resulted in over 80 publications and 18 patents on the development of technologies for drug discovery. He has a Ph.D. in Chemistry and an MBA with a concentration in Pharmaceuticals and Helathcare.